IM Cannabis (NASDAQ:IMCC) versus DiaSorin (OTCMKTS:DSRLF) Head-To-Head Review

IM Cannabis (NASDAQ:IMCC) and DiaSorin (OTCMKTS:DSRLF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings for IM Cannabis and DiaSorin, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1	0	0	0	1.00
DiaSorin	0	0	2	0	3.00

Earnings & Valuation

This table compares IM Cannabis and DiaSorin”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.44 million	0.23	-$7.72 million	($0.78)	-2.26
DiaSorin	$1.28 billion	N/A	$203.55 million	N/A	N/A

DiaSorin has higher revenue and earnings than IM Cannabis.

Insider and Institutional Ownership

7.7% of IM Cannabis shares are held by institutional investors. 5.9% of IM Cannabis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

IM Cannabis has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500. Comparatively, DiaSorin has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500.

Profitability

This table compares IM Cannabis and DiaSorin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-9.47%	-134.35%	-11.66%
DiaSorin	N/A	N/A	N/A

Summary

DiaSorin beats IM Cannabis on 7 of the 10 factors compared between the two stocks.

About IM Cannabis

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.